Adverse Events of Lutetium-177-PSMA-617 Revealed
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic castration-resistant cases that express prostate-specific...